Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy

Ana Lledó a,*, Miriam Retuerto a,#, Patricia Almendro-Vázquez b, Mario Fernández-Ruiz c, María Galindo a, M. R. Laguna-Goya b, Estela Paz-Artal b, Antonio Lalueva d, José M. Aguado c, José L. Pablos a,*,

a Department of Rheumatology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
b Department of Immunology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
c Department of Medicine, Universidad Complutense, Madrid, Spain
d Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

A R T I C L E    I N F O

Keywords:
SARS-CoV-2
COVID-19
T-cell response
interferon-γ
rheumatic diseases
immunosuppressive therapy.

A B S T R A C T

Background: In patients with immune-mediated rheumatic diseases (RMD), the development of T-cell responses against SARS-CoV-2 may be impaired by either the immune disturbances associated with the disease, or by the effects of immunosuppressive therapies. We aimed at determining the magnitude of SARS-CoV-2-specific interferon (IFN)-γ-producing T-cell response after COVID-19 recovery in a cohort of patients with RMD on different immunosuppressive therapies.

Patients and methods: 53 adult patients with inflammatory or autoimmune RMD and 61 sex and age-matched non-RMD patients with confirmed COVID-19 were included. Peripheral blood mononuclear cells were obtained and T-cell-IFN-γ antigen-specific responses against the S1 domain of the spike glycoprotein, the nucleoprotein (N) and the membrane (M) protein from SARS-CoV-2 were assessed by FluoroSpot assay.

Results: Patients with RMD and COVID-19 showed positive T-cells-IFN-γ responses to SARS-CoV-2 antigens, in a similar proportion and magnitude as non-RMD patients at a median of 298 [151–316] and 165 [162–167] days after COVID-19 respectively. Among RMD patients 83%, 87% and 90%, and among non-RMD patients, 95%, 87% and 93% responded to S1, N and M protein respectively. Similar responses were observed in the different diagnostic and therapeutic groups, including conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), TNF-α inhibitors, IL-17 inhibitors, rituximab, JAK inhibitors or other immunosuppressants.

Conclusion: T-cell responses to the main SARS-CoV-2 antigens are present after COVID-19 recovery in most patients with RMD and are not impaired by immunosuppressive therapies.

© 2021 Elsevier Inc. All rights reserved.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated illness coronavirus disease 2019 (COVID-19) may have a greater impact in patients with rheumatic disease (RMD), particularly in patients with systemic autoimmune diseases and those under immunosuppressive therapy. Age, comorbidities, RMD activity and some therapies represent a potential risk factor for severe illness in these patients (1–3).

Humoral IgG responses are detected in the general population within the first weeks from COVID-19 symptom onset, and persist at least 6–8 months after infection, displaying a decreasing trend over time (4). SARS-CoV-2-specific CD4 and CD8 memory T-cells with robust interferon (IFN)-γ responses are positive in most patients up to nearly one year after infection, and seem to play an essential role in long lasting immunity (5). Similarly, upon SARS-CoV-2 vaccination, T-cell responses are achieved after the first dose and may complement the protective effects of neutralizing antibodies (6). In patients with autoimmune diseases, the development of protective adaptive immune responses against SARS-CoV-2 may be impaired by either the immune disturbances associated with autoimmune disease, or by the effects of immunosuppressive therapies as observed in other groups such as solid organ transplanted (SOT) patients (7).

In response to SARS-CoV-2 vaccines, defective humoral responses have been identified in RMD patients on methotrexate (MTX), mycophenolate, rituximab (RTX) or abatacept, whereas JAK inhibitors and biologic therapies such as TNF-α, IL6 or IL-17 inhibitors do not seem
to hamper seroconversion (8). However, information on T-cell responsiveness in these patients after COVID-19 is lacking. Recent data show that T-cell specific responses to SARS-CoV-2 vaccines are preserved in most RMD patients on different immunosuppressive, although their magnitude is reduced in some groups (9-12).

Since increasing evidence supports a relevant role of T-cell responses in protection after infection or vaccination, understanding the potential interference of immunosuppressive therapies or RMD on the development of these responses after COVID-19 recovery may help to predict potential risks in these patients. We aimed at determining the magnitude of SARS-CoV-2–specific IFN-γ-producing T-cells after COVID-19 recovery in a cohort of RMD patients.

Materials and methods

Study population

Adult patients with inflammatory or autoimmune RMD with laboratory-confirmed COVID-19 by either reverse transcription polymerase chain reaction (RT-PCR) or IgG serologic testing (Supplementary Methods) between March 2020 and January 2021 at the University Hospital “12 de Octubre” (Madrid, Spain) were eligible for inclusion. A similar group of age- and sex-matched patients without RMD, other immune-mediated disease, or immunosuppressive therapy, was also identified and used as control group. None of the included individuals had been vaccinated against SARS-CoV-2.

The study was carried out in accordance with Helsinki Declaration ethical standards and the study protocol was approved by the local institutional Research Ethics Committee (ref. 20/314). All participants provided written informed consent.

SARS-CoV-2 T-cell responses assessment by IFN-γ fluorospot assay

Peripheral blood mononuclear cells (PBMCs) were freshly isolated within 8 h from sampling by density-gradient centrifugation using Ficoll-Paque and seeded at 300,000 cells/well in IFN-γ FluoroSpot plates (MabTech, Nacka Strand, Sweden) with cell culture medium containing RPMI, 1% L-glutamine, 1% penicillin/streptomycin, 10% fetal bovine serum and anti-CD28 mAb (1 μg/mL). Test wells were performed in duplicate and supplemented with 15-mer overlapping peptides covering the S1 domain of the S glycoprotein (166 peptides) (SARS-CoV-2 S1 scanning pool, MabTech), the nucleoprotein (N protein) (102 peptides) (Epitope Mapping Peptide Set [EMPS] SARS-CoV-2 NCP-1, JPT), and the membrane (M) protein (53 peptides) (EMPS SARS-CoV-2 VME1, JPT) at a final concentration of 1 μg/mL. Sample-specific negative and positive control wells for each patient were included. Negative control wells lacked peptides, and positive control wells included anti-CD3 mAb (MabTech). Assays were incubated for 16–18 h at 37 °C. Spots were counted using an automated IRIS™ FluoroSpot Reader System (MabTech).

To quantify antigen-specific responses, spots of the negative control wells were subtracted from the mean spots of test wells, and the results were expressed as IFN-γ–producing spot forming units (SFUs) per 10^6 PBMCs. Results were excluded if negative control wells had >80 SFUs/10^6 PBMCs or positive control wells had <400 SFUs/10^6 PBMCs. Reponses were considered positive if the results were at least three times higher than the mean of the negative control wells and above the following antigen-specific cut-off values (which had been established by using a control group of 30 healthy volunteers with no microbiological or clinical evidence of SARS-CoV-2 infection): >25 SFUs/10^6 PBMCs for the S glycoprotein, >14 SFUs/10^6 PBMCs for the N protein, and >21 SFUs/10^6 PBMCs for the M protein. PBMCs were used in this assay, however, results regarding the specific cellular immune response are expressed as T cell response. T cells constitute the largest fraction of isolated PBMCs and are the main producers of IFN-γ.

Statistical analysis

Quantitative data were shown as the mean ± SD or the median with interquartile range (IQR). Categorical variables were compared using the χ^2 or Fisher exact test. Mann-Whitney U test was applied to compare the magnitude of SARS-CoV-2–specific IFN-γ-producing T-cell responses between both groups. Bonferroni adjustment for multiple testing was used. Statistical analyses were performed with STATA/IC version 14.0 (Stata Corp) and GraphPad Prism 5 (GraphPad, Inc).

Results

Study population

We recruited 53 patients with RMD and 61 age- and sex-matched patients without rheumatic diseases and a confirmed COVID-19 diagnosis. Age, sex, and the presence of relevant comorbidities were similar in both groups (Table 1). The median duration of the rheumatic disease was 7 years (IQR 3–11). The RMD diagnostics, therapy, and clinical characteristics of COVID-19 are shown in Table 1.

Among those patients who received specific COVID-19 treatment (40%), the most common treatment regimes included antiviral therapy with lopinavir/ritonavir in 6 (11%) and remdesivir in 1 (2%), and/or immunosuppressive treatment with glucocorticoids in 9 (17%) and IL-6 inhibitors in 3 (6%). Conversely, none of the patients in the non-RMD group received remdesivir and 26 (43%) were given IL-6 or IL-1 inhibitors, or glucocorticoids. Severity of COVID-19 infection was greater in non-RMD patients, those were in all cases hospitalized, whereas RMD cohort also included non-hospitalized patients under follow-up at our rheumatology unit (Table 1). The interval between symptomatic COVID-19 and T-cell response testing was significantly longer in the group of RMD patients (Table 1).

T-cell-IFN-γ-producing responses to SARS-CoV-2 antigens

Positive SARS-CoV-2–specific T-cell-IFN-γ–producing responses to S1, N, or M proteins were detected in most patients with or without RMD. Globally, patients with RMD showed positive T-cell IFN-γ responses to each of the three tested SARS-CoV-2 antigens after COVID-19, in a statistically similar proportion as non-RMD patients (Table 2). Four patients did not respond to any of the three antigens (two RMD and two non-RMD patients). Among RMD patients 83%, 87% and 90%, and among non-RMD patients, 95%, 87% and 93% responded to S1, N and M protein respectively. A non-significant numerical difference was only observed for S1 protein responders. Responses to S1 protein were not detected in three of the non-RMD group (5%) and in nine of the RMD group (17%). Among RMD patients not responding to S1 protein, three were on csDMARDs, three on low dose glucocorticoids, one on TNF-α inhibitor, one on IL17-inhibitor, and one on azathioprine.

The proportion of responders among RMD patients was not modified by the severity of COVID-19 infection nor by the time between COVID-19 and T-cell response testing (Supplementary Table S1 and supplementary Figure S1). No differences in the magnitude of T-cell-IFN-γ response to each individual antigen in hospitalized versus non-hospitalized patients were found in the RMD group (Supplementary Table S2).

The magnitude of the IFN-γ–producing T-cell response to SARS-CoV-2 antigens was also similar strength of the RMD and non-RMD groups as shown in Fig. 1A and Supplementary Table S3. A similar level of response was also observed independently of the therapy received (Fig. 1B) or the diagnosis (Fig. 1C). No differences were found in the level of response at different intervals after COVID-19 diagnosis neither in RMD nor in non-RMD group (Supplementary Figure S1).
Table 1
Demographics and clinical characteristics of the study population.

|                              | Rheumatic n = 53 | Non-Rheumatic n = 61 | p-value |
|------------------------------|------------------|----------------------|---------|
| Age                          | 53 (44–61)*      | 53 (49–66)           | 0.365   |
| Female sex                   | 40 (75)          | 42 (69)              | 0.433   |
| Comorbiditiesa               | 27 (51)          | 28 (46)              | 0.555   |
| Rheumatic disease diagnosis  |                  |                      |         |
| Rheumatoid arthritis         | 20 (38)          |                      |         |
| Psoriatic arthritis          | 7 (13)           |                      |         |
| Spondyloarthritis            | 11 (21)          |                      |         |
| Systemic lupus erythematosus (SLE) | 8 (15)        |                      |         |
| AI/IMID non-SLE              | 7 (13)           |                      |         |
| Baseline rheumatic disease medications |       |                      |         |
| Glucocorticoids              | 17 (32)          |                      |         |
| Hydroxychloroquine           | 15 (28)          |                      |         |
| Methotrexate                 | 16 (30)          |                      |         |
| Leflunomide                  | 4 (8)            |                      |         |
| Sulfasalazine                | 6 (11)           |                      |         |
| Azathioprine                 | 4 (8)            |                      |         |
| Calcineurin inhibitors       | 1 (2)            |                      |         |
| Mycophenolate                | 4 (8)            |                      |         |
| TNFα inhibitor               | 10 (19)          |                      |         |
| IL-17 inhibitor              | 6 (11)           |                      |         |
| Rituximab                    | 4 (8)            |                      |         |
| JAK inhibitors               | 4 (8)            |                      |         |
| Active disease               | 10 (19)          |                      |         |

| Covid-19 associated variables | 298 (151–316) | 160 (162–167) | <0.001 |
|------------------------------|---------------|---------------|--------|
| Follow-up from diagnosis to T-cell testing Hospitalization n = 114 |               |               |        |
| 17 (32)                      |               |               |        |
| Radiographic pneumonia, n = 114 | 21 (40)      |               | <0.001 |
| Respiratory failure, n = 114 | 10 (19)       | 34 (56)       | <0.001 |
| Clinical severity Low-flow nasal cannula (FiO2<40%) | 9 (17)        | 22 (36)       | 0.022  |
| High-flow nasal cannula (FiO2≥40%) | 4 (8)        | 11 (18)       | 0.099  |
| Non-invasive ventilation | 0 (0)         | 2 (3)         | 0.184  |
| Intensive care unit admission | 2 (4)        | 4 (7)         | 0.684  |
| Treatment Antiviral therapyb | 7 (13)        | 41 (67)       | <0.001 |
| Immunosuppressive treatmentf | 9 (17)        | 26 (43)       | <0.005 |

* Values represent n (%) or median (IQR).

a Comorbidities: obesity, diabetes mellitus, hypertension, cardiovascular disease, lung disease.

c AI/IMID non-SLE: polymyositis, cryoglobulinemia, granulomatosis with polyangiitis, Sjogren’s syndrome, systemic sclerosis.

d FiO2: fraction of inspired oxygen.

e Antiviral therapy: lopinavir/ritonavir or remdesivir.

The proportion of responders and the magnitude of the T-cell responses to each of the SARS-CoV-2 proteins in RMD and non-RMD patients treated with glucocorticoids or anti-cytokine (anti-IL-6 or anti-IL-1) as therapy for COVID-19 were similar to those in the group of not treated with immunosuppressive agents (data not shown).

Discussion

Whether SARS-CoV-2 infection confers immunity to reinfection and for how long is yet uncertain. At this point, more than one year after the first cases were diagnosed in Europe, reinfection rates are very low and most cases are milder than the first episode, pointing to a long-lasting protective immunity (13). Immunity relies on both IgG antibodies that can neutralize S-protein-receptor interaction, and T-cell effector responses against several structural viral antigens in infected cells (14). Whereas IgG antibodies seem to rapidly decline, memory T-cells seem responsible for long-lasting protection (5).

In patients with compromised immune responses, the development of both T-cell and humoral immunity after immunization is usually hampered (8). However, in solid organ transplant (SOT) recipients recovered from COVID-19, T-cell responses against SARS-CoV-2 antigens do not seem different in magnitude or duration compared to the general population (15-17). In these patients, the humoral and cellular responses to SARS-CoV-2 vaccines were significantly lower (7,18). Several conventional or biologic immunosuppressive therapies may also reduce the response to SARS-CoV-2 vaccines in patients with RMD, including high dose glucocorticoids, mycophenolate, or rituximab, although T-cell responses are usually better preserved than humoral responses (9-12). These patients might remain at higher risk for COVID-19 despite vaccination, but data on the incidence are lacking. In a large cohort of inflammatory bowel disease (IBD) patients on different immunosuppressive regimes, clinical effectiveness of vaccines was similar to what reported in the general population, but the therapies in these patients and RMD patients can be different (19).

In this study, we have observed that most patients with rheumatic diseases under different immunosuppressive therapies achieve a T-cell immune response after natural SARS-COV-2 infection. We did not find differences in T-cell responses in relation to the different diseases or immunosuppressive therapies. More than 80% of the patients achieve a response under csDMARDs, bDMARDs (biologic disease-modifying anti-rheumatic drugs), JAK inhibitors or other immunosuppressants such as mycophenolate or calcineurin inhibitors. Remarkably, all rituximab or JAK inhibitors treated patients, although in small numbers, showed positive responses. Whereas humoral and
cellular response to SARS-COV-2 vaccines may be impaired in SOT recipients and RMD patients, T-cell responses in patients recovered from COVID-19 in both groups seem comparable to those in the general population (7-10, 15-18).

We acknowledge that our study has some limitations. First the population is quite heterogeneous in diagnosis and other clinical characteristics, and although comparable to the control group, it differs in two potentially important variables. First, COVID-19 severity was higher in non-RMD control group, which only included hospitalized patients on follow-up after recovery. Patients with milder disease were not followed-up, precluding their inclusion. Instead, either milder or severe patients with RMD were followed-up at our rheumatology unit. In previous studies, cellular or humoral immune responses were not found different between severe or mild disease (14, 20). In our RMD patients, differences between hospitalized or non-hospitalized patients were not found. Also, the timing from COVID-19 to T-cell response determination was significantly longer in RMD patients, but this might have led to decreased rather than increased responses in this group and therefore, it also supports the conclusion on the T-cell responsiveness of these patients.

Although this study has shown an adequate cellular immune response in rheumatic patients after SARS-COV-2 infection, further studies should be conducted to clarify the durability and preventive capacity of this response.

Declaration of Competing Interest

Ana Lledó, Miriam Retuerto, Patricia Almendro-Vázquez, Mario Fernández-Ruiz, María Galindo, Rocío Laguna-Goya, Estela Paz-Artal, Antonio Lalueza, José María Aguado and José L. Pablos do not have financial information to disclose.

---

Table 2

| T-cell-IFN-γ producing responses to SARS-COV-2 antigenic peptides. |
|------------------|------------------|------------------|
|                   | S1 - 25<sup>a</sup> | N - 14<sup>b</sup> | M - 21<sup>c</sup> |
| Non-rheumatic cohort n = 61 | 58 (95)<sup>3</sup> | 53 (87) | 57 (93) |
| Rheumatic cohort n = 53 | 44 (83)<sup>3</sup> | 46 (87) | 48 (90) |
| Rheumatic disease diagnosis | | | |
| Rheumatoid arthritis | 16 (80) | 16 (80) | 17 (85) |
| Psoriatic arthritis | 6 (86) | 7 (100) | 6 (85<sup>c</sup>7) |
| Spondylarthropathies | 9 (81) | 10 (91) | 10 (91) |
| Systemic lupus erythematosus (SLE) | 7 (88) | 7 (86) | 8 (100) |
| AI/IMID non-SLE<sup>d</sup> | 6 (86) | 6 (86) | 7 (100) |
| Baseline rheumatic disease medications | | | |
| Glucocorticoids | 14 (82) | 13 (77) | 17 (100) |
| Conventional synthetic DMARDs (csDMARDs)<sup>e</sup> | 17 (85) | 18 (90) | 18 (90) |
| TNF-α inhibitor | 9 (90) | 10 (100) | 9 (90) |
| IL-17 inhibitor | 5 (83) | 6 (100) | 5 (83) |
| Rituximab | 4 (100) | 4 (100) | 4 (100) |
| JAK inhibitors | 4 (100) | 4 (100) | 4 (100) |
| Other immunosuppressants (IS)<sup>f</sup> | 8 (89) | 8 (89) | 9 (100) |

---

Fig. 1. Magnitude of T-cell-IFN-γ producing responses to SARS-CoV-2 antigens. A) T-cell-IFN-γ response (SFU) to S1, M and N antigens in RMD and non-RMD groups. B) T-cell-IFN-γ response across different therapies. Other IS include azathioprine, mycophenolate and calcineurin inhibitors. C) T-cell-IFN-γ response across the different RMD. Data represent median and IQR. Black dots represent patients without positive response (<25 SFU for S glycoprotein; <14 SFU for N protein and <21 SFU for the M protein). Others: non-SLE autoimmune disease.
Acknowledgements

This work was supported by the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 Research Call COV20/00181), co–funded by European Development Regional Fund “A way to achieve Europe”. M.F.R. holds a research contract “Miguel Servet” (CP18/00073) and R.L.G. a research contract “Río Horta” (CM19/00120), both from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation. M.R. received a physician investigator grant from Sociedad Española de Reumatología.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.semarthrit.2021.10.006.

References

[1] Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021;80(7):930–42.

[2] Avouac J, Drumez E, Hachulla E, Servo R, Georgin-Lavalie S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, Donnet F, Chazerain P, Devaux M, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. The Lancet. Rheumatology 2021;3(6): e419–26.

[3] Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020;79(12):1544–9.

[4] Dan JM, Mateus J, Kato Y, Hastei KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021 Feb 5;371(6529):eabf4063.

[5] Yao L, Wang G-L, Shen Y, Wang Z-Y, Zhan B-D, Duan Ll-J, et al. Persistence of Anti-SARS-CoV-2 antibodies in COVID-19 patients over Nine Months after infection. J Infect Dis 2021 May 12.

[6] Poland GA, Osvyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. The Lancet 2020;396:1595–606.

[7] Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 2021 Apr 18. doi: 10.1111/ajt.16615.

[8] Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with auto-immune inflammatory rheumatic diseases and in the general population: a multi-centre study. Ann Rheum Dis 2021;1–9.

[9] Mahil SK, Bechman K, Raharja A, Domingo-vila C, Baudry D, Brown MA, et al. Articles The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2 : a cohort study. Lancet Rheumatol 2021;9:913(21):1–11.

[10] Mirak D, Tobudic S, Kohlbischke M, Graninger M, Radner H, Sieghart D, et al. SARS-CoV-2 vaccination in rituximab-treated patients: b cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis 2021;80:1345–50.

[11] Picchianti-Diamanti A, Aiello A, Lagana B, Agrati C, Castilletti C, Meschi S, et al. Immunosuppressive Therapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. Front Immunol 2021;12:740249.

[12] Prenderick M, Clarke C, Edwards H, McIntyre S, Mortimer P, Gleeson S, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 2021;80:1322–9.

[13] Pan L, Wang R, Yu N, Hu C, Yan J, Zhang X, et al. Clinical characteristics of re-hospitalized COVID-19 patients with recurrent positive SARS-CoV-2 RNA: a retrospective study. Eur J Clin Microbiol Infect Dis 2021;40(6):1245–52.

[14] Weiskopf D, Immunol S, Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, et al. Phenotypic and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol 2020;5:eabd2071.

[15] Minotti C, Tirelli F, Barbieri E, Giaquinto C, Dona D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J Infect 2020;81(1):e61–6.

[16] Fernández-Ruiz M, Olea B, Almendro-Vázquez P, Giménez E, Marcacuzco A, et al. T cell-mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19. Am J Transplant 2021 Jun 5. doi: 10.1111/ajt.16708.

[17] Fernández-Ruiz M, Olea B, Giménez E, Laguna-Goya R, Trujillo H, et al. SARS-CoV-2-specific Cell-mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19. Transplantation 2021 Jun 1;105(6):1372–80.

[18] Havlin J, Svorcova M, Dvorakova E, Lastovicka J, Lischke R, et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. J Heart Lung Transplant 2021;40:754–8.

[19] Khan N, Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs Cohort of Inflammatory Bowel Disease Patients with Diverse Exposure to Immunosuppressive Medications. Gastroenterology 2021 May 25;S0016-5085(21):03063–6.

[20] Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell 2021;184:169–83 e17.